The hypoglycemic action of SGLT2-I by excreting glucose in the urine may make a decisive difference in treating type 2 DM because, unlike insulin secretagogues and other hypoglycemic drugs that stimulate insulin secretion, SGLT2-I does not induce hyperinsulinemia [6]. Here, INS is linked to hyperinsulinism.